top of page
Welcome to Prof. Ming-Hon Hou's Laboratory at NCHU

 Ming-Hon Hou (教授資訊)

侯老師個人照.jpg

Lab 712 Members (實驗室成員)

256754.jpg

Research Topics (研究方向)

pulish.jpg

Overview

In order to solve the health problems that human beings are facing today, our research focuses on the development of novel drugs against several important infectious diseases, genetic diseases, and cancers. 

Our major research projects include:

  1. Development of antiviral drugs targeting the nucleocapsid protein against emerging viruses.

  2. Development of anticancer drugs targeting DNA or RNA.

  3. Development of diagnostic tools for genetic diseases associated with unusual DNA structures.

HorizontalFIgures.tiff

January 2024- Our new study on targeting protein-protein interaction interfaces for anti-viral drug discovery has been accepted to publish in the Biophysical Journal. Congratulations Prof. Hou and team.

May 2023- Our new study about myotonic dystrophy type 1 causing CUG RNA repeat has been accepted to publish in the Journal of Biological Chemistry. Congratulations Prof. Ming-Hon Hou, Prof. Jhih-Wei Chu and our team!

May 2023- Our research paper on AI based machine learning model has been published in the journal Frontiers in Medicine. Congratulations Prof. Ming-Hon Hou, Dr. Kuo-Yang Huang and the team!

February 2023- Congratulations Prof. Hou and team for accepting their new manuscript in Nucleic Acids Research.

興大人物誌|十年磨一劍 興大侯明宏教授投入抗冠狀病毒藥物開發

新冠肺炎疫情再度升溫,確診人員屢破新高。中興大學5月份發行《興大人物誌》影片,紀錄基因體暨生物資訊學研究所教授侯明宏從2003年SARS爆發至今,投入冠狀病毒研究的歷程。十多年來他孤軍奮戰,直至2020年3月,所提出以核殼蛋白作為冠狀病毒藥物開發標的之研究,終登《藥物化學》國際期刊封面,至今下載次數破萬,為全球抗冠狀病毒藥物開展新方向。

2022學術能量專區—生命科學領域教師專訪(中興大學基因體暨生物資訊學研究所 侯明宏教授主講)

 

|講題|

  2022學術能量專區—生命科學領域教師專訪

 

|講者|中興大學基因體暨生物資訊學研究所 侯明宏教授

We welcome you to join "Nucleic Acids: Prospect and Therapeutic Applications"
at
National Chung Hsing University
on 
July, 07, 2023

unnamed.jpg

We are happy to share a new website for our upcoming event this year in 2022......

Screenshot 2022-03-13 150224.jpg

For more info contact:

Find us:

  • Facebook
  • Twitter
bottom of page